關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「D-Link」新聞搜尋結果， 共 14869 篇 ，以下為 409 - 432 篇 訂閱此列表，掌握最新動態
Global Business News
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports. The NOBLE (Nobody Left Behind) Registry (NOBLE) is a global real-world evidence (RWE) study that aims to improve equity of access to state-of-the-art prostate cancer imaging. NOBLE is a collaboration combining the oncology and prostate cancer expertise of the Oncidium foundation as registry sponsor, Telix's intellectual property, and partnered clinical and operational support. An international network of sites support the registry locally through Principal Investigators (PIs), who are responsible for initiating and conducting research. Investigators collect patient data that will inform the development of TLX599-CDx, an investigational prostate cancer imaging agent that targets PSMA[1] using 99m-technetium (99mTc)-based SPECT[2] imaging. SPECT cameras are being clinically evaluated in this application because they are more widely available than the PET/CT[3] scanners used for gallium- or fluorine-based PSMA imaging, where access can be limited by socio-economic or geographic factors, as well as healthcare funding models. For every PET scanner available globally, there are four SPECT machines[4], making them a more accessible option when used with 99mTc – a radionuclide with a well-established supply chain, which can be produced in a bench-top generator. In the publication, the investigators report initial results based on a study of 40 patients in six countries[5], who received TLX599-CDx followed by planar and SPECT imaging. Investigators reported a change in management for 17 patients (42.5%) due to the use of SPECT-based PSMA imaging. No adverse events were reported. The authors conclude that technetium-based imaging "is a promising option to identify PSMA-positive prostate cancer on SPECT and could improve patient access to PSMA imaging worldwide", fulfilling an unmet need for millions of patients with prostate cancer who do not have straightforward access to PET imaging. Pete Tually, lead author, Director, TeleMed Remote Nuclear Medicine, and Principal Investigator for the Australian arm of NOBLE said, "The NOBLE Registry is an important initiative for increasing access to medicine globally, particularly for men in regional and remote locations. The interim results reported in our manuscript are promising, and we believe they provide a compelling basis for the further clinical study of technetium-99m-based PSMA imaging of prostate cancer." Rebecca Lo bue, CEO, Oncidium foundation, added, "PSMA-PET[6] imaging is today widely used in many countries worldwide, helping to extend life and improve treatment outcomes for men with prostate cancer through earlier diagnosis and better disease management. However, millions of men do not have access to this technology. These results from NOBLE represent an exciting milestone in bringing to market a powerful, cost-effective, and widely available alternative imaging tool that uses PSMA-SPECT technology." Dr. David N. Cade, Group Chief Medical Officer, Telix, continued, "Telix is proud to support the NOBLE Registry, which aims to improve access for patients who face geographic or economic barriers to state-of-the-art prostate cancer imaging. This publication by Pete Tually and his co-authors[7] signals a positive future for technetium-99m-based PSMA imaging, and we are excited to be part of this innovative program. As established leaders in PSMA imaging, Telix is committed to exploring multiple avenues to help men with prostate cancer get the diagnoses and treatments they need. We would like to thank all NOBLE investigators and the patients who have contributed towards this study." The EJNMMI Reports publication is available online at:https://link.springer.com/article/10.1186/s41824-024-00226-4 Telix and the Oncidium foundation are planning follow-on clinical activity for NOBLE. This may include collaboration with Rhine Pharma on expanded access or compassionate use programs, exploring the use of technetium-99m and rhenium-188 as a theranostic pair for prostate cancer. This initiative reflects Telix's global commitment to access to medicine. About the Oncidium foundation The Oncidium foundation is a nonprofit organisation dedicated to advancing global access to radioligand therapy for cancer care. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, supporting and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients, globally. For more information visit http://www.oncidiumfoundation.org About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], and by Health Canada[10]. No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. [1] Prostate-specific membrane antigen. [2] Single photon emission computed tomography. [3] Positron emission tomography/computed tomography. [4] MEDraysintell. [5] Australia, Azerbaijan, Egypt, Indonesia, Mexico, South Africa. [6] Imaging of prostate-specific membrane antigen with positron emission tomography. [7] Virginia Garcia Quinto (Hospital Galenia Department of Nuclear Medicine, Cancun, Mexico), Yehia Omar (Misr Radiology Center, Cairo, Egypt), Fuad Novruzov (Department of Nuclear Medicine, Azerbaijan National Centre of Oncology, Baku, Azerbaijan), Ryan Yudistiro (Department of Nuclear Medicine, Siloam Hospital, Jakarta, Indonesia), Mike Sathekge (University of Pretoria Nuclear Medicine Department, Gauteng, South Africa), Geoffrey Currie (School of Dentistry and Medical Sciences, Charles Sturt University, Bathurst, Australia), Paul Galette, Neel Patel, Tracey Brown and David Cade (Telix), Gabriel Bolland and Rebecca Lo bue (Oncidium foundation). [8] Telix ASX disclosure 20 December 2021. [9] Telix ASX disclosure 2 November 2021. [10] Telix ASX disclosure 14 October 2022.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 512 加入收藏 :
Global Business News
Dataloy Caps Off 2024 with Record Growth and Q4 Innovations Driving Maritime Excellence

Closing 2024 with close to 25% revenue growth, including a strong fourth quarter, Dataloy Systems continues to strengthen its position in maritime digitalisation. BERGEN, Norway, Dec. 30, 2024 /PRNewswire/ -- Dataloy Systems, a global leader in voyage management solutions, concludes 2024 on a high note, celebrating a transformative year with close to 25% revenue growth and a strong fourth quarter marked by innovative product updates and expanded tools to meet the shipping industry's evolving needs. Q4 Highlights: A Strong Finish to a Transformative Year The final quarter of 2024 saw Dataloy delivering on its promise of innovation and customer-centricity, achieving: Customer Expansion: Q4 saw a 15% increase in new customers, driven by adoption from dry bulk and tanker operators, contributing to a remarkable 25% revenue growth for the full year. Key Product Releases: Introduction of new features such as enhanced VMS collaboration tools and further advancements in Dataloy Widgets, delivering contextual insights for faster, more informed decision-making. Innovating to Solve Industry Challenges In Q4, Dataloy focused on solutions that address the shipping industry's most pressing needs: Simplified Compliance for EU ETS, FuelEU and CII: New updates provide customers with seamless tools to navigate emission regulations while improving operational efficiency. Mobile Voyage Management: Dataloy's mobile platform, available for over two years, has been fine-tuned with customer feedback to optimise usability and integrate seamlessly with evolving operational needs. Enhanced Collaboration Features: Tools like comments and mentions, and secure URL-sharing for voyage details reduce miscommunication and speed up decision-making. "Our Q4 performance reflects Dataloy's commitment to delivering value where it matters most-helping our customers adapt and thrive in a complex regulatory and operational environment," said Erik Fritz Loy, CEO of Dataloy Systems. "With close to 25% growth this year and a strong Q4 driven by 15% new customer growth, we are proud of what we've achieved in 2024 and look forward to building on this momentum as we enter 2025." Looking Ahead: What's Next for Dataloy Dataloy enters the new year with ambitious plans to continue empowering the maritime industry through technology and innovation: Widget Ecosystem Expansion: Rolling out additional widgets integrated with leading data providers for richer contextual insights. Focus on Sustainability: Enhancing tools that support customers in meeting decarbonisation goals and simplifying regulatory compliance. Customer and Partner Summit: A Q2 2025 event bringing together industry leaders to shape the future of maritime technology. About Dataloy Dataloy Systems is a leading provider of voyage management systems, delivering cutting-edge tools that simplify operations, improve compliance, and drive efficiency for the shipping industry. With a focus on innovation and customer-centricity, Dataloy empowers its partners to navigate a rapidly evolving maritime landscape. This information was brought to you by Cision http://news.cision.com https://news.cision.com/dataloy-systems/r/dataloy-caps-off-2024-with-record-growth-and-q4-innovations-driving-maritime-excellence,c4087004 Contact : Anumita Bhargava; +47 9886 7908; abh@dataloy.com 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 445 加入收藏 :
Global Business News
THE RITZ-CARLTON, BALI CELEBRATES 10 YEARS ANNIVERSARY

A Decade of Legendary Service in Award-Winning Beachfront Resort BALI, Indonesia, Dec. 27, 2024 /PRNewswire/ -- The Ritz-Carlton, Bali, a premier beachfront destination renowned for its breathtaking views, world-class amenities, and unparalleled guest experiences, is proud to announce its 10th anniversary. Since opening its doors in 2014, the resort has welcomed guests from around the globe to experience the beauty and tranquility of Nusa Dua, Bali. The Ritz-Carlton, Bali "This milestone reflects our commitment to creating unforgettable memories for our guests while embracing the natural beauty of our surroundings," said Go Kondo, General Manager of The Ritz-Carlton, Bali. "We are deeply grateful to our loyal guests, dedicated team, and supportive community for making this journey possible." Over the past decade, The Ritz-Carlton, Bali has earned numerous accolades, including Forbes Travel Guide, Travel+Leisure World Best Awards, Travel+Leisure Luxury Awards Asia Pacific, Exquisite Awards, DestinAsian Reader's Choice Awards, Condé Nast Traveler Readers' Choice Awards, solidifying its reputation as a leading destination in luxury beachfront hospitality. The latest collaboration with an Italian fashion house, Missoni and The Ritz-Carlton brand to launch the first Missoni Resort Club at The Ritz-Carlton, Bali, marks the highlight of the ten years of excellence. Link to more images: https://marrstar.box.com/s/0lu99jz4osy9hdy2s0zpfe5gp9f8t8da For reservations and inquiries, please call (+62) 361 849 8988, or visit http://www.ritzcarltonbali.com for more information about The Ritz-Carlton Bali or connect on WhatsApp (+62) 8191 849 8988. ABOUT THE RITZ-CARLTON, BALI Built on a sprawling 12.7 hectares white beach front and elevated  cliff  top  settings,  The  Ritz-Carlton, Bali feature 313 oceanfront suites and villas, enjoying the unobstructed view of the Indian Ocean and the resort's lush garden. Completing the experiences, a glass elevator connects the cliff and the beach-front, five restaurants and bars, The Ritz-Carlton Ballroom and meeting facilities, a wedding chapel, as well as The Ritz-Carlton Spa. Ladies and gentlemen at The Ritz-Carlton, Bali is proudly presents the timeless charms of Indo-Balinese hospitality. ABOUT THE RITZ-CARLTON HOTEL COMPANY, L.L.C. The Ritz-Carlton Hotel Company, L.L.C. of Chevy Chase, Md., currently operates 88 hotels in the Americas, Europe, Asia, the Middle East, Africa, and the Caribbean. More than 30 hotel and residential projects are under development around the globe.  The Ritz-Carlton is the only service company to have twice earned the prestigious Malcolm Baldrige National Quality Award, which recognizes outstanding customer service. For more information, or reservations, contact a travel professional, call toll free in the U.S. 1-800-241-3333, or visit the company web site at www.ritzcarlton.com. The Ritz-Carlton Hotel Company, L.L.C. is a wholly owned subsidiary of Marriott International, Inc. (NASDAQ:  MAR)

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 343 加入收藏 :
大陸港澳
Digital Realty 為 Turing 的 Gaggle Cluster 提供了頂尖的數據中心基礎設施，幫助其透過 AI 加速全面自動駕駛的發展

一個穩健靈活並可支援 AI 自動駕駛大型 GPU 叢集的平台，輔助 Turing 產品開發上市速度提高 75% 新加坡2024年12月30日 /美通社/ -- 世界領先的雲端運算和運營商中立數據中心、主機託管和互聯解決方案供應商 Digital Realty (NYSE: DLR) 今天宣布，日本人工智能 (AI) 公司 Turing, Inc. 已在 Digital Realty 位於日本東京的 NRT10 數據中心部署最先進的運算平台，以支持全自動駕駛技術的發展。 Turing 是全面自動駕駛技術開發方面的先驅，正致力研發一套點到點的自動駕駛系統。該系統藉助 AI 技術，通過車輛攝像頭收集的數據，來實現對車輛轉向、加速和煞車等所有駕駛功能的操控。Turing 為了推動自動駕駛技術的發展，開發了「Heron」（一個能夠利用文字及視覺數據進行複雜決策的多模態生成式 AI）和「Terra」（一個能理解複雜現實情境並生成逼真駕駛場景視頻的生成式實景模型）。Turing 目前正集中精力研發旗艦項目「Tokyo30」，計劃在 2025 年底前，在東京市區實現至少 30 分鐘的 Level 5 全自動駕駛。 為了實現這個計劃，Turing 開發了名為 Gaggle Cluster 的強大運算平台，該平台配備了96塊NVIDIA H100 GPU。NRT10 是一個經認證可支援 NVIDIA DGX 並配備高密度電源供應的數據中心，是一個能最大化 GPU 效能及效率的理想環境。 NRT10 由 Digital Realty 與日本三菱商事株式會社（Mitsubishi Corporation）的合資企業 MC Digital Realty 運營，是 Digital Realty 全球數據中心平台 PlatformDIGITAL® 的重要組成部分。該設施為 Turing 提供多項主要優勢，包括： 加速開發上市效率：與內部部署建置相比， Turing 的 AI 開發時間表從一年大幅縮短到僅三個月。 可立即部署的高密度託管解決方案：NRT10 的模組化設計有助實現快速配置和部署。此外，NRT10 的高密度託管服務讓 Turing 能夠將其基礎架構從 20 個機架優化為僅 8 個機架，這不僅提升了效率，也保障了可擴展性。 最大化 GPU 效能：NRT10 的先進冷卻技術和電源供應系統能確保最佳的 GPU 效能及效率。 彈性擴充：NRT10 的園區式配置可根據 Turing 需求的增長進行輕鬆靈活的擴展。 Turing 技術總監 Yu Yamaguchi 表示：「隨著全球競相開發全面自動駕駛系統的步伐加快，迅速確保運算資源變得至關重要。Digital Realty 高效能且靈活的數據中心令我們能夠在短時間內迅速部署一個強大的 GPU 叢集，發揮最大效能，進一步加速我們在全面自動駕駛方面的 AI 開發進程。」 Digital Realty 董事總經理兼亞太區主管 Serene Nah 表示：「Digital Realty 很高興能夠走在這個崛起的前端，運用我們豐富的人工智能經驗及專業知識，支持 Turing 的突破性 AI 創新。我們提供的高效能且靈活的數據中心環境，讓 Turing 能夠快速部署和擴充其關鍵的 AI 運算。這項合作不僅加速了 Turing 全面自動化技術的研發進程，還為 AI 解決方案的效能和效率樹立了新的標杆。我們致力於協助 Turing 和其他創新公司實現他們的目標，透過我們的高階 AI 基礎架構和前瞻性的數據中心解決方案，共同塑造未來世界的運作方式。」 關於 Digital RealtyDigital Realty 透過提供全方位數據中心、主機託管和互聯解決方案，使企業和數據得以結合。公司的全球數據中心平台 PlatformDIGITAL® 為客戶提供安全的數據匯集處，並提供經驗證的 Pervasive Datacenter Architecture (PDx®) 解決方案，推動以創新高效的方法應對數據引力挑戰。Digital Realty 的全球數據中心遍佈六大洲逾 25 個國家、50 多個主要城市及 300 多個設施，協助客戶進入其重視的互聯社群。有關 Digital Realty 的資訊，請瀏覽 digitalrealty.com 或在 LinkedIn 和 X 上追蹤我們。 詳情請聯絡 傳媒聯絡 Sin Huay HoDigital Realty+65 8125 8380shho@digitalrealty.com 投資者關係Jordan Sadler / Jim HusebyDigital Realty+1 415 275 5344InvestorRelations@digitalrealty.com 免責聲明本新聞稿包含基於當前預期、預測和假設的前瞻性陳述，涉及可能導致實際結果和結果存在重大差異的風險和不確定性，諸如與公司發展前景、對日本及日本市場增長的預期、客戶對公司產品和服務需求、PlatformDIGITAL®、以及公司的可持續發展計劃、目標和成就等方面的陳述。有關風險和不確定性的清單及說明，請參閱公司向美國證券交易委員會提交的報告和其他檔案。公司並無計劃或義務更新或修改任何前瞻性聲明，無論是出於新資訊、未來事件還是其他原因。

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1104 加入收藏 :
Seven-time world champion Ronnie O’Sullivan in action at the 2024 Hong Kong Snooker All-Star Challenge.
Global Business News
How Hong Kong offers top talents their next big break

HONG KONG SAR - Media OutReach Newswire - 30 December 2024 - Snooker superstars Ronnie O'Sullivan and Judd Trump are among the latest high-profile talents to become Hong Kong residents under the city's Quality Migrant Admission Scheme (QMAS), which facilitates top quality professionals from various fields to live and work in Hong Kong. Seven-time world champion Ronnie O’Sullivan in action at the 2024 Hong Kong Snooker All-Star Challenge. Seven-time world champion O'Sullivan and current world No.1 Trump, both frequent visitors to the city, are looking forward to spending more time in Hong Kong and embarking on a new phase of their careers. "I am here because I enjoy the city; I love everything about Hong Kong – the food, the people, and the buildings. It is inspiring for me to be here," said Trump, who announced his successful QMAS application last week (December 24). "For me, I really enjoy the energy in Hong Kong, so I love to be around people and I love to see people thriving and go about their business." O'Sullivan was delighted to announce his residency under the scheme on October 31. "Your food, your culture, it's just a great place to live; a great place to be," he said. "If you're going to live your life and you want to have a good life, you should come to Hong Kong." O'Sullivan and Trump will compete in front of their new "home" crowd during the World Grand Prix at the soon-to-open Kai Tak Sports Park (KTSP) in March 2025. World No.1 Judd Trump during the 2024 Hong Kong Snooker All-Star Challenge. It will be one of the first major sports events at KTSP, a state-of-the-art 28-hectare venue, which is set to transform Hong Kong's sports and entertainment landscape. Secretary for Labour and Welfare, Chris Sun, hailed the effectiveness of the QMAS. "We hope to achieve more success, because we truly believe in the attraction of Hong Kong. Be it our tax system, our natural beauty, the convenience, the great food and all the great things here in Hong Kong," Sun said. Hong Kong Talent Engage is a one-stop platform to attract and assist top professionals and people with valuable skills and experience to live and work in Hong Kong and enhance the city's economic competitiveness. QMAS is one of several talent attraction schemes to attract highly skilled or talented persons globally to Hong Kong. Hashtag: #hongkong #brandhongkong #asiasworldcity #snooker #talent #HKTalentEngagehttps://www.brandhk.gov.hk/https://www.linkedin.com/company/brand-hong-kong/https://x.com/Brand_HK/https://www.facebook.com/brandhk.isdhttps://www.instagram.com/brandhongkongThe issuer is solely responsible for the content of this announcement.

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 313 加入收藏 :
大陸港澳
雅特力科技2024年終畫卷｜與時偕行，再啟「芯」程

台北2024年12月30日 /美通社/ -- 歲序更新之際，雅特力科技向大家致以新年的美好祝福！2024年，我們憑藉專業實力與技術突破，在快速變化的市場中穩步前行，收穫了豐碩成果與成就，並為未來的成功打下堅實基礎。在展望2025年之際，我們誠邀您一起回顧過去一年雅特力的高光時刻，共同迎向更加輝煌的新里程。 雅特力科技：致敬2024，創新邁向2025 銳意創新，穩步邁向「精而專」發展之路 雅特力科技成立於2016年，專注於32位微控制器（MCU）的研發與創新，產品涵蓋工業控制、電機、車載、消費電子、新能源等領域。我們以先進製程與ARM® Cortex®-M4/M0+架構，為全球市場提供高效能、高可靠性的解決方案。自2018年起，雅特力已推出近20個MCU系列，助力客戶實現智慧應用與產業升級，至今累計銷量已達數億顆。隨著全球工業自動化、智慧家居與電動工具市場的蓬勃發展，雅特力以領先的MCU技術與研發能力，為市場提供全面的技術支援。 2024年，雅特力推出多款備受市場矚目的產品，包含： AT32L021低功耗系列MCU 2月推出，雅特力首款入門級低功耗MCU，支援多種能耗模式（如睡眠模式與低功耗模式）及快速喚醒功能。其最小封裝僅3x3mm，特別適用於便攜式設備、無線感測器、OBD、BMS、RF工業控制、無線通訊模組及物聯網設備等小空間與電池供電應用。 AT32A423車規級MCU 5月上市，通過AEC-Q100車規級認證，具備高效能、多尺寸封裝、高度抗干擾性和穩定性能，適用於車身控制、ADAS輔助駕駛、車載影音系統及新能源車BMS等應用場景，在汽車市場中展現出強大競爭力。 AT32M412/M416電機控制專用MCU 10月推出，針對電機驅動應用場景設計，具備高速運算效能、精準性及穩定性，滿足市場對高性能與高可靠性電機控制解決方案的需求。廣泛應用於電動兩輪車、電動摩托車、助力車、洗衣機、壓縮機、變頻器、工業風機、伺服電機及電動工具等。 多元佈局，「市場+生態」齊頭並進 雅特力持續發力中高端市場，在工業控制、電機、車載、智能家電等市場持續拓展，2024年推出了攀爬車電子調速器、智慧車載座椅、車載盲區檢測可視盒、8K電競滑鼠、智能家居控制台、智能IO模組、工業切膜機等市場應用，並構建了完善的開發生態體系，為產品開發注入加速度。 雅特力2024年聚焦AT32 MCU的應用與技術成果，包括： AT32 Workbench圖形化代碼生成工具 這款圖形化的嵌入式開發工具為MCU工程師提供便捷的初始化C語言代碼生成功能，並支援多種平台（如Windows®與Linux®），顯著簡化開發流程。同時，AT32 Workbench還相容主流開發環境，包括Keil、IAR及AT32 IDE，幫助用戶輕鬆進行跨平台移植與開發。 AT32 MCU與SEGGER攜手合作 雅特力與SEGGER共同宣佈，J-Link模擬器與Flasher燒錄器全面支援AT32 MCU產品，透過SEGGER工具鏈的高效支援，嵌入式開發效率大幅提升，加速量產進程。 通過IEC 60730功能安全認證 雅特力AT32 MCU安全庫順利通過IEC 60730功能安全認證，為家電產品提供運行中的安全性與可靠性保障，進一步提升市場信任。此認證由國際知名檢測機構SGS頒發，彰顯了雅特力在家電控制領域的卓越品質與技術實力。 基於AT32 MCU的洗衣機電機控制驅動方案 雅特力以卓越的性能和穩定性，提供高效的電機控制驅動方案。該方案支持智慧家居應用，特別適用於洗衣機以及電動兩輪車和電動摩托車等需求多樣的產品，並已實現規模量產，滿足市場對穩定與效率的高度期待。 基於AT32 MCU的多功能一體機應用方案 雅特力為多功能一體機（包括列印、掃描、復印與傳真等功能）提供高效的運算支援，實現多功能設備的穩定性與安全性。並結合聯網功能，確保系統運行的高效穩定，並有效防範數據隱私洩露風險。 向上突破，「品牌+產品」屢獲市場認可 在競爭日益激烈的市場環境中，雅特力始終堅持自主發展，聚焦使用者需求，專注提升產品性能和品質。憑藉在MCU產品市場中高效能和高可靠性，以及相對完善的開發生態等顯著優勢，贏得了客戶的廣泛信賴與認可，推動行業健康可持續發展。 2024年雅特力科技的榮譽包括： 榮獲「2024年度電機控制十大主控晶片」： 11月21日，雅特力AT32F415於電子發燒友舉辦的2024電機控制先進技術研討會中憑藉其高效性能和卓越市場表現，榮獲「2024年度電機控制十大主控晶片」獎。 榮獲第十九屆「中國芯」優秀市場表現產品獎： 11月7日，在橫琴舉辦的中國微電子產業促進大會中，雅特力AT32F421系列以市場卓越表現榮獲此殊榮。 雅特力科技榮獲「2024年BLDC電機控制器行業 創芯突破獎」： 11月1日，雅特力AT32M412/M416於深圳的BLDC電機控制器年度評選中，憑藉其卓越性能榮獲創新突破獎。 雅特力科技蟬聯「重慶市軟件和資訊服務企業五十強」： 7月18日，於重慶舉辦的中國工業軟件大會中，雅特力再次入選綜合競爭力榜單，顯示我們在軟體與訊息服務領域的持續領先。 雅特力AT32F405高速USB MCU榮獲「年度最佳MCU」： 3月29日，在上海舉行的國際集成電路展覽會暨研討會（IIC Shanghai）中，雅特力憑藉其在高速USB應用中的出色表現，榮獲「年度最佳MCU」殊榮。 雅特力亮相2024慕尼黑上海電子展 7月8日，2024慕尼黑上海電子展在上海新國際博覽中心開幕，匯聚國內外優質電子企業，打造科技盛宴。雅特力攜高性能AT32 MCU及多款電機控制、工業控制、汽車電子、智慧家居、新能源等應用方案參展，現場人潮湧動，氛圍熱烈！ 展望未來：攜手全球，智創2025展望2025年，雅特力將以更廣闊的視野，聚焦科技革新與市場需求，致力於打造全球化的微控制器生態系統。我們將依託跨國研發與技術團隊，結合先進製程與自主核心技術，不斷推出高效能、高可靠性的嵌入式解決方案。 未來，雅特力將致力於促進智慧應用的廣泛實現與行業轉型升級，攜手全球合作夥伴，共同書寫科技驅動智慧未來的新篇章。

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1129 加入收藏 :
ARTERY 2024: Redefining MCU Innovation for a Smarter Future
發表時間 :
Announcement of change in the total number of votes in AB SKF
發表時間 :
Proud Real Estate Unveils Romm Convent: The Apex of Luxury Wellness Residences in Bangkok’s Vibrant CBD
發表時間 :
Collector-Turned-Entrepreneur Opens House of Watches’ First Store at Far East Plaza
發表時間 :
特許房屋經理學會亞太分會週年會議2024圓滿結束
發表時間 :
屈臣氏繼續拓展GCC業務 於巴林開設全新旗艦店
發表時間 :
Watsons Continues its Expansion in GCC with the Opening of its New Flagship Store in Bahrain
發表時間 :
BEST Inc. Malaysia: Pioneering Innovation and Redefining Logistics Excellence
發表時間 :
Vietnam Leads Surge in Contactless Payments Across Asia-Pacific: Visa survey data
發表時間 :
Helsinki's Cultural Highlights for 2025: A Year of Design, Art, and Celebration
發表時間 :
Live Fish from Zhongshan to Macao in Just Two Hours
發表時間 :
Yuewen Music Festival Day 1: Mesmerizing Performances Ignites Siloso Beach, Sentosa
發表時間 :
EQT to Exit Indian Renewable Energy Platform O2 Power
發表時間 :
Pigeon Empowers Mothers With A Holistic Maternity Skincare Line: The Perfect Blend of Nature, Science, and Sustainability
發表時間 :
VinFast VF 8 Demonstrates the Upstart Carmaker’s Ambition to Succeed
發表時間 :
XCMG Ranks 379th on the 2024 World's 500 Most Influential Brands List, Leading Innovation in Industrial Equipment
發表時間 :
XCMG Launches Used Equipment Certification to Drive Sustainable Development in Construction Machinery
發表時間 :
Xinhua Silk Road: Conference on deepening financial openness and co-op in Northeast Asia held in NE. China's Shenyang
發表時間 :
2025 年 1 月 20 日 (星期一) 農曆十二月廿一日
A12 藝術空間
TradeAsia 亞洲貿易網 | 開啟全球商機的專業 B2B 貿易平台 Web Builder 智慧型網站大師 | 網站建置的領導品牌
2025 亞洲文具及辦公用品展覽會 2024 亞洲運動休閒展覽會 台灣五金展(THS) 台灣金屬材料暨精密加工設備展(IMT)
亞洲貿易展 益陽工業股份有限公司 良英股份有限公司 複成企業股份有限公司 亞洲網址銀行 Bath Sponge, Shopping Bag, Cosmetic Bag Manufacturer - NETBRIDGE
首 頁 我的收藏 搜 尋 新聞發佈